Christian Sandøe Musaeus,Troels Wesenberg Kjaer,Melita Cacic Hribljan et al.
Christian Sandøe Musaeus et al.
Background: Patients with dementia with Lewy bodies (DLB) have a higher probability of seizures than in normal aging and in other types of neurodegenerative disorders. Depositions of α-synuclein, a pathological hallmark ...
Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks [0.03%]
基于手指敲击任务的治疗检测及运动障碍学会帕金森病评价量表Ⅲ篇的评估方法研究
Ahnjili ZhuParris,Eva Thijssen,Willem O Elzinga et al.
Ahnjili ZhuParris et al.
The validation of objective and easy-to-implement biomarkers that can monitor the effects of fast-acting drugs among Parkinson's disease (PD) patients would benefit antiparkinsonian drug development. We developed composite biomarkers to det...
Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design [0.03%]
基于历史帕金森病试验的纵向元分析指导未来试验设计
Usman Arshad,Fatima Rahman,Nathan Hanan et al.
Usman Arshad et al.
Background: The outcome of clinical trials in neurodegeneration can be highly uncertain due to the presence of a strong placebo effect. Objectives: ...
Alu Retrotransposition Event in SPAST Gene as a Novel Cause of Hereditary Spastic Paraplegia [0.03%]
SPAST基因中的Alu回文事件是遗传性双侧瘫痪的新致病因素
Yi-Jun Chen,Meng-Wen Wang,Yu-Sen Qiu et al.
Yi-Jun Chen et al.
Objectives: To diagnose the molecular cause of hereditary spastic paraplegia (HSP) observed in a four-generation family with autosomal dominant inheritance. ...
Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs [0.03%]
来自鼻拭子和口腔拭子的帕金森病特异性microRNA标志物的检测
Patricia Schließer,Felix L Struebing,Bernd H Northoff et al.
Patricia Schließer et al.
Background: Biomaterials from oral and nasal swabs provide, in theory, a potential resource for biomarker development. However, their diagnostic value has not yet been investigated in the context of Parkinson's disease (P...
Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients [0.03%]
帕金森病门诊患者报告结果的瑞典语量表的有效性研究
Daniel von Below,Susanna M Wallerstedt,Filip Bergquist
Daniel von Below
Background: Successful treatment of Parkinson's disease (PD) requires symptom monitoring. Patient-Reported Outcomes in Parkinson's Disease (PRO-PD) is a broad scale that covers 35 motor and nonmotor symptoms, but its vali...
Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease [0.03%]
亨廷顿舞蹈病的纵向影像学研究和地区脑结构容积、SV2A及葡萄糖代谢的关系
Aline Delva,Koen Van Laere,Wim Vandenberghe
Aline Delva
Background: Development of disease-modifying treatments for Huntington's disease (HD) could be aided by the use of imaging biomarkers of disease progression. Positron emission tomography (PET) with 11 C-UCB-J, a radioliga...
Konstantin Senkevich,Mariia Beletskaia,Aliza Dworkind et al.
Konstantin Senkevich et al.
Background: Several lysosomal genes are associated with Parkinson's disease (PD), yet the association between PD and ARSA remains unclear. Objectives: ...
Gian Pal,Lola Cook,Jeanine Schulze et al.
Gian Pal et al.
Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct-to-co...